by The pulmonary arterial hypertension market size is poised to grow by USD 12.18 billion by 2032 from USD 7.3 billion in 2022, exhibiting a CAGR of 5.30% during the forecast period 2023-2032.
Key Takeaways
- North America led the market with the largest market share of 41% in 2022.
- Asia-Pacific is projected to grow at a notable CAGR of 13.3% during the forecast period.
- By Drug Class, the prostacyclin and prostacyclin analogs segment has held the major revenue share of 45% in 2022.
- By Drug Class, The SGC simulators segment is anticipated to grow at a CAGR of 5% during the projected period.
- By Type, the branded segment contributed more than 42% of revenue share in 2022.
- By Type, the generics segment is projected to grow at the fastest CAGR over the projected period.
- By Route of Administration, the oral segment generated more than 51% of revenue share in 2022.
- By Route of Administration, the intravenous/ subcutaneous segment is expected to expand at the fastest CAGR over the projected period.
Precedence Research has conducted a comprehensive market study that provides valuable insights into the performance of the market during the forecast period. The study identifies significant trends that are shaping the growth of the Pulmonary arterial hypertension market. In this recently published report, essential dynamics such as drivers, restraints, and opportunities are highlighted for both established market players and emerging participants involved in production and supply.
To begin with, the Pulmonary arterial hypertension Market report features an executive summary that offers a concise overview of the marketplace. It outlines the key players and industry categories expected to have an impact on the market in the coming years. The executive summary provides an unbiased summary of the market.
Get a Sample Report: https://www.precedenceresearch.com/sample/3432
Pulmonary Arterial Hypertension Market Scope
| Report Coverage | Details |
| Growth Rate from 2023 to 2032 | CAGR of 5.3% |
| Market Size in 2023 | USD 7.65 Billion |
| Market Size by 2032 | USD 12.18 Billion |
| Largest Market | North America |
| Base Year | 2022 |
| Forecast Period | 2023 to 2032 |
| Segments Covered | By Drug Class, By Type, and By Route of Administration |
| Regions Covered | North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa |
Read More: Fiber Based Packaging Market Poised to Exceed $527.71 Bn By 2032
The empirical study on the global Pulmonary arterial hypertension market primarily focuses on the drivers in subsequent sections. It demonstrates how changing demographics are projected to influence the supply and demand dynamics in the Pulmonary arterial hypertension Market. Our market report for the Pulmonary arterial hypertension market also delves into the significant rules and regulations that are likely to impact the future growth of this sector. Moreover, in order to comprehend the underlying demand factors, industry experts have provided insights into its fundamental origins.
Top Key Players:
- Actelion Pharmaceuticals (now part of Janssen Pharmaceuticals)
- Gilead Sciences
- United Therapeutics Corporation
- GlaxoSmithKline
- Bayer
- Pfizer
- Arena Pharmaceuticals
- Reata Pharmaceuticals
- Lung Biotechnology
- Acceleron Pharma
- Liquidia Technologies
- SteadyMed Therapeutics (acquired by United Therapeutics)
- Complexa Inc.
- Bellerophon Therapeutics
- Innoven Life Sciences.
Data Sources and Methodology
To gather comprehensive insights on the Global Pulmonary arterial hypertension Market, we relied on a range of data sources and followed a well-defined methodology. Our approach involved interactions with industry experts and key stakeholders across the market’s value chain, including management organizations, processing organizations, and analytics service providers.
We followed a rigorous data analysis process to ensure the quality and credibility of our research. The gathered information was carefully evaluated, and relevant quantitative data was subjected to statistical analysis. By employing robust analytical techniques, we were able to derive meaningful insights and present a comprehensive overview of the Global Pulmonary arterial hypertension Market.
The most resonating, simple, genuine, and important causes because of which you must decide to buy the Pulmonary arterial hypertension market report exclusively from precedence research
- The research report has been meticulously crafted to provide comprehensive knowledge on essential marketing strategies and a holistic understanding of crucial marketing plans spanning the forecasted period from 2023 to 2032.
Key Features of the Report:
- Comprehensive Coverage: The report extensively encompasses a detailed explanation of highly effective analytical marketing methods applicable to companies across all industry sectors.
- Decision-Making Enhancement: It outlines a concise overview of the decision-making process while highlighting key techniques to enhance it, ensuring favorable business outcomes in the future.
- Articulated R&D Approach: The report presents a well-defined approach to conducting research and development (R&D) activities, enabling accurate data acquisition on current and future marketing conditions.
Market Segmentation:
By Drug Class
- Endothelin Receptor Antagonists (ERAs)
- PDE-5 Inhibitors
- Prostacyclin and Prostacyclin Analogs
- SGC Stimulators
By Type
- Branded
- Generics
By Route of Administration
- Oral
- Intravenous/ subcutaneous
- Inhalational
By Geography
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East and Africa
Reasons to Consider Purchasing the Report:
- Enhance your market research capabilities by accessing this comprehensive and precise report on the global Pulmonary arterial hypertension market.
- Gain a thorough understanding of the overall market landscape and be prepared to overcome challenges while ensuring robust growth.
- Benefit from in-depth research and analysis of the latest trends shaping the global Pulmonary arterial hypertension market.
- Obtain detailed insights into evolving market trends, current and future technologies, and strategic approaches employed by key players in the global Pulmonary arterial hypertension market.
- Receive valuable recommendations and guidance for both new entrants and established players seeking further market expansion.
- Discover not only the cutting-edge technological advancements in the global Pulmonary arterial hypertension market but also the strategic plans of industry leaders.
Table of Content
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology (Premium Insights)
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Pulmonary Arterial Hypertension Market
5.1. COVID-19 Landscape: Pulmonary Arterial Hypertension Industry Impact
5.2. COVID 19 – Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Pulmonary Arterial Hypertension Market, By Drug Class
8.1. Pulmonary Arterial Hypertension Market, by Drug Class, 2023-2032
8.1.1 Endothelin Receptor Antagonists (ERAs)
8.1.1.1. Market Revenue and Forecast (2020-2032)
8.1.2. PDE-5 Inhibitors
8.1.2.1. Market Revenue and Forecast (2020-2032)
8.1.3. Prostacyclin and Prostacyclin Analogs
8.1.3.1. Market Revenue and Forecast (2020-2032)
8.1.4. SGC Stimulators
8.1.4.1. Market Revenue and Forecast (2020-2032)
Chapter 9. Global Pulmonary Arterial Hypertension Market, By Type
9.1. Pulmonary Arterial Hypertension Market, by Type, 2023-2032
9.1.1. Branded
9.1.1.1. Market Revenue and Forecast (2020-2032)
9.1.2. Generics
9.1.2.1. Market Revenue and Forecast (2020-2032)
Chapter 10. Global Pulmonary Arterial Hypertension Market, By Route of Administration
10.1. Pulmonary Arterial Hypertension Market, by Route of Administration, 2023-2032
10.1.1. Oral
10.1.1.1. Market Revenue and Forecast (2020-2032)
10.1.2. Intravenous/ subcutaneous
10.1.2.1. Market Revenue and Forecast (2020-2032)
10.1.3. Inhalational
10.1.3.1. Market Revenue and Forecast (2020-2032)
Chapter 11. Global Pulmonary Arterial Hypertension Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Drug Class (2020-2032)
11.1.2. Market Revenue and Forecast, by Type (2020-2032)
11.1.3. Market Revenue and Forecast, by Route of Administration (2020-2032)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Drug Class (2020-2032)
11.1.4.2. Market Revenue and Forecast, by Type (2020-2032)
11.1.4.3. Market Revenue and Forecast, by Route of Administration (2020-2032)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Drug Class (2020-2032)
11.1.5.2. Market Revenue and Forecast, by Type (2020-2032)
11.1.5.3. Market Revenue and Forecast, by Route of Administration (2020-2032)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Drug Class (2020-2032)
11.2.2. Market Revenue and Forecast, by Type (2020-2032)
11.2.3. Market Revenue and Forecast, by Route of Administration (2020-2032)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Drug Class (2020-2032)
11.2.4.2. Market Revenue and Forecast, by Type (2020-2032)
11.2.4.3. Market Revenue and Forecast, by Route of Administration (2020-2032)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Drug Class (2020-2032)
11.2.5.2. Market Revenue and Forecast, by Type (2020-2032)
11.2.5.3. Market Revenue and Forecast, by Route of Administration (2020-2032)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Drug Class (2020-2032)
11.2.6.2. Market Revenue and Forecast, by Type (2020-2032)
11.2.6.3. Market Revenue and Forecast, by Route of Administration (2020-2032)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Drug Class (2020-2032)
11.2.7.2. Market Revenue and Forecast, by Type (2020-2032)
11.2.7.3. Market Revenue and Forecast, by Route of Administration (2020-2032)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Drug Class (2020-2032)
11.3.2. Market Revenue and Forecast, by Type (2020-2032)
11.3.3. Market Revenue and Forecast, by Route of Administration (2020-2032)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Drug Class (2020-2032)
11.3.4.2. Market Revenue and Forecast, by Type (2020-2032)
11.3.4.3. Market Revenue and Forecast, by Route of Administration (2020-2032)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Drug Class (2020-2032)
11.3.5.2. Market Revenue and Forecast, by Type (2020-2032)
11.3.5.3. Market Revenue and Forecast, by Route of Administration (2020-2032)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Drug Class (2020-2032)
11.3.6.2. Market Revenue and Forecast, by Type (2020-2032)
11.3.6.3. Market Revenue and Forecast, by Route of Administration (2020-2032)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Drug Class (2020-2032)
11.3.7.2. Market Revenue and Forecast, by Type (2020-2032)
11.3.7.3. Market Revenue and Forecast, by Route of Administration (2020-2032)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Drug Class (2020-2032)
11.4.2. Market Revenue and Forecast, by Type (2020-2032)
11.4.3. Market Revenue and Forecast, by Route of Administration (2020-2032)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Drug Class (2020-2032)
11.4.4.2. Market Revenue and Forecast, by Type (2020-2032)
11.4.4.3. Market Revenue and Forecast, by Route of Administration (2020-2032)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Drug Class (2020-2032)
11.4.5.2. Market Revenue and Forecast, by Type (2020-2032)
11.4.5.3. Market Revenue and Forecast, by Route of Administration (2020-2032)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Drug Class (2020-2032)
11.4.6.2. Market Revenue and Forecast, by Type (2020-2032)
11.4.6.3. Market Revenue and Forecast, by Route of Administration (2020-2032)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Drug Class (2020-2032)
11.4.7.2. Market Revenue and Forecast, by Type (2020-2032)
11.4.7.3. Market Revenue and Forecast, by Route of Administration (2020-2032)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Drug Class (2020-2032)
11.5.2. Market Revenue and Forecast, by Type (2020-2032)
11.5.3. Market Revenue and Forecast, by Route of Administration (2020-2032)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Drug Class (2020-2032)
11.5.4.2. Market Revenue and Forecast, by Type (2020-2032)
11.5.4.3. Market Revenue and Forecast, by Route of Administration (2020-2032)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Drug Class (2020-2032)
11.5.5.2. Market Revenue and Forecast, by Type (2020-2032)
11.5.5.3. Market Revenue and Forecast, by Route of Administration (2020-2032)
Chapter 12. Company Profiles
12.1. Actelion Pharmaceuticals (now part of Janssen Pharmaceuticals)
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Gilead Sciences
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. United Therapeutics Corporation
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. GlaxoSmithKline
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Bayer
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Pfizer
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Arena Pharmaceuticals
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Reata Pharmaceuticals
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Lung Biotechnology
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Acceleron Pharma
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
Unlocking Market Insights through Data Excellence
The “Precedence Statistics” flexible dashboard is a powerful tool that offers real-time news updates, economic and market forecasts, and customizable reports. It can be configured to support a wide range of analysis styles and strategic planning needs. This tool empowers users to stay informed and make data-driven decisions in various scenarios, making it a valuable asset for businesses and professionals looking to stay ahead in today’s dynamic and data-driven world.
Access our Premium Real Time Data Intelligence Tool, Visit: www.precedencestatistics.com
Precedence Statistics – Empowering Your Data Insights
Contact Us
Precedence Research
Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
